PURPOSE: To determine the safety of the mammalian target of rapamycin inhibitor everolimus (RAD001) administered daily with concurrent radiation and temozolomide in newly diagnosed glioblastoma patients. METHODS AND MATERIALS: Everolimus was administered daily with concurrent radiation (60 Gy in 30 fractions) and temozolomide (75 mg/m(2) per day). Everolimus was escalated from 2.5 mg/d (dose level 1) to 5 mg/d (dose level 2) to 10 mg/d (dose level 3). Adjuvant temozolomide was delivered at 150 to 200 mg/m(2) on days 1 to 5, every 28 days, for up to 12 cycles, with concurrent everolimus at the previously established daily dose of 10 mg/d. Dose escalation continued if a dose level produced dose-limiting toxicities (DLTs) in fewer than 3 of the first 6 evaluable patients. RESULTS: Between October 28, 2010, and July 2, 2012, the Radiation Therapy Oncology Group 0913 protocol initially registered a total of 35 patients, with 25 patients successfully meeting enrollment criteria receiving the drug and evaluable for toxicity. Everolimus was successfully escalated to the predetermined maximum tolerated dose of 10 mg/d. Two of the first 6 eligible patients had a DLT at each dose level. DLTs included gait disturbance, febrile neutropenia, rash, fatigue, thrombocytopenia, hypoxia, ear pain, headache, and mucositis. Other common toxicities were grade 1 or 2 hypercholesterolemia and hypertriglyceridemia. At the time of analysis, there was 1 death reported, which was attributed to tumor progression. CONCLUSIONS: Daily oral everolimus (10 mg) combined with both concurrent radiation and temozolomide followed by adjuvant temozolomide is well tolerated, with an acceptable toxicity profile. A randomized phase 2 clinical trial with mandatory correlative biomarker analysis is currently under way, designed to both determine the efficacy of this regimen and identify molecular determinants of response.
PURPOSE: To determine the safety of the mammalian target of rapamycin inhibitor everolimus (RAD001) administered daily with concurrent radiation and temozolomide in newly diagnosed glioblastomapatients. METHODS AND MATERIALS: Everolimus was administered daily with concurrent radiation (60 Gy in 30 fractions) and temozolomide (75 mg/m(2) per day). Everolimus was escalated from 2.5 mg/d (dose level 1) to 5 mg/d (dose level 2) to 10 mg/d (dose level 3). Adjuvant temozolomide was delivered at 150 to 200 mg/m(2) on days 1 to 5, every 28 days, for up to 12 cycles, with concurrent everolimus at the previously established daily dose of 10 mg/d. Dose escalation continued if a dose level produced dose-limiting toxicities (DLTs) in fewer than 3 of the first 6 evaluable patients. RESULTS: Between October 28, 2010, and July 2, 2012, the Radiation Therapy Oncology Group 0913 protocol initially registered a total of 35 patients, with 25 patients successfully meeting enrollment criteria receiving the drug and evaluable for toxicity. Everolimus was successfully escalated to the predetermined maximum tolerated dose of 10 mg/d. Two of the first 6 eligible patients had a DLT at each dose level. DLTs included gait disturbance, febrile neutropenia, rash, fatigue, thrombocytopenia, hypoxia, ear pain, headache, and mucositis. Other common toxicities were grade 1 or 2 hypercholesterolemia and hypertriglyceridemia. At the time of analysis, there was 1 death reported, which was attributed to tumor progression. CONCLUSIONS: Daily oral everolimus (10 mg) combined with both concurrent radiation and temozolomide followed by adjuvant temozolomide is well tolerated, with an acceptable toxicity profile. A randomized phase 2 clinical trial with mandatory correlative biomarker analysis is currently under way, designed to both determine the efficacy of this regimen and identify molecular determinants of response.
Authors: José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: Carolyn Cao; Ty Subhawong; Jeffrey M Albert; Kwang Woon Kim; Ling Geng; Konjeti R Sekhar; Young Jin Gi; Bo Lu Journal: Cancer Res Date: 2006-10-15 Impact factor: 12.701
Authors: Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel Journal: N Engl J Med Date: 2005-11-10 Impact factor: 91.245
Authors: Jann N Sarkaria; Evanthia Galanis; Wenting Wu; Patrick J Peller; Caterina Giannini; Paul D Brown; Joon H Uhm; Steven McGraw; Kurt A Jaeckle; Jan C Buckner Journal: Int J Radiat Oncol Biol Phys Date: 2010-09-23 Impact factor: 7.038
Authors: Eric T Shinohara; Carolyn Cao; Ken Niermann; Yi Mu; Fenghua Zeng; Dennis E Hallahan; Bo Lu Journal: Oncogene Date: 2005-08-18 Impact factor: 9.867
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Jeffrey S Eshleman; Brett L Carlson; Ann C Mladek; Brian D Kastner; Kathleen L Shide; Jann N Sarkaria Journal: Cancer Res Date: 2002-12-15 Impact factor: 12.701
Authors: Prakash Chinnaiyan; Minhee Won; Patrick Y Wen; Amyn M Rojiani; Maria Werner-Wasik; Helen A Shih; Lynn S Ashby; Hsiang-Hsuan Michael Yu; Volker W Stieber; Shawn C Malone; John B Fiveash; Nimish A Mohile; Manmeet S Ahluwalia; Merideth M Wendland; Philip J Stella; Andrew Y Kee; Minesh P Mehta Journal: Neuro Oncol Date: 2018-04-09 Impact factor: 12.300
Authors: Manuel Valdivieso; Benjamin W Corn; Janet E Dancey; D Lawrence Wickerham; L Elise Horvath; Edith A Perez; Alison Urton; Walter M Cronin; Erica Field; Evonne Lackey; Charles D Blanke Journal: Semin Oncol Date: 2015-07-10 Impact factor: 4.929
Authors: Taemin Oh; Michael E Ivan; Matthew Z Sun; Michael Safaee; Shayan Fakurnejad; Aaron J Clark; Eli T Sayegh; Orin Bloch; Andrew T Parsa Journal: Immunotherapy Date: 2014 Impact factor: 4.196
Authors: Daniel J Ma; Evanthia Galanis; S Keith Anderson; David Schiff; Timothy J Kaufmann; Patrick J Peller; Caterina Giannini; Paul D Brown; Joon H Uhm; Steven McGraw; Kurt A Jaeckle; Patrick J Flynn; Keith L Ligon; Jan C Buckner; Jann N Sarkaria Journal: Neuro Oncol Date: 2014-12-18 Impact factor: 12.300
Authors: Benjamin M Ellingson; Jingwen Yao; Catalina Raymond; David A Nathanson; Ararat Chakhoyan; Jeremy Simpson; James S Garner; Alan G Olivero; Lars U Mueller; Jordi Rodon; Elizabeth Gerstner; Timothy F Cloughesy; Patrick Y Wen Journal: Clin Cancer Res Date: 2020-04-08 Impact factor: 12.531